Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 7/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9220859 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL26088568 | 0.77 | TSHR (0.52) | SMN1; SMN2SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL26088571 | 0.77 | TSHR (0.52) | SMN1; SMN2SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL19668097 | 0.76 | SLC6A2 (0.47) | SMN1; SMN2SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL19668081 | 0.76 | SLC6A2 (0.47) | SMN1; SMN2SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL19668060 | 0.76 | SLC6A2 (0.47) | SMN1; SMN2SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL4171082 | 0.76 | MAOB (0.48) | SMN1; SMN2SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL4171085 | 0.76 | MAOB (0.48) | SMN1; SMN2SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL4171081 | 0.76 | MAOB (0.48) | SMN1; SMN2SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL4790557 | 0.76 | SMN1; SMN2 (0.46) | SMN1; SMN2SLC6A2ADRA1AHTR2BSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117624131-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117624130-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-116323565-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-7714167-B2 | Catalytic asymmetric epoxidation | UNIVERSITY OF CHICAGO (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714167-B2 | Catalytic asymmetric epoxidation | UNIVERSITY OF CHICAGO (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090170902-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | US | disclosed |
| US-20090170902-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | US | disclosed |
| US-20090170902-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | US | disclosed |
| EP-1706205-B1 | A CATALYTICAL ASYMMETRIC EPOXIDATION | UNIV CHICAGO (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1981864-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-22 | — | — | EP | disclosed |
| US-20070203347-A1 | Catalytic asymmetric epoxidation | THE UNIVERSITY OF CHICAGO (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203347-A1 | Catalytic asymmetric epoxidation | THE UNIVERSITY OF CHICAGO (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2007090841-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090841-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
| US-7202371-B2 | Catalytic asymmetric epoxidation | THE UNIVERSITY OF CHICAGO (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202371-B2 | Catalytic asymmetric epoxidation | THE UNIVERSITY OF CHICAGO (US) | 2007-04-10 | — | — | US | disclosed |
| US-4146384-A | Tetrahydrofuran-ether compounds and herbicidal compositions | BAYER AKTIENGESELLSCHAFT (DE) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203347-A1 | Catalytic asymmetric epoxidation | DUOX1, DUOX2, EPHX2 | SMN1; SMN2 4555/4885SLC6A2 4259/4885ADRA1A 1853/4885 |
| US-20090170902-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GRIN1, GRM1, GRIN2C | SMN1; SMN2 2659/4885SLC6A2 218/4885ADRA1A 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.